| Dr Aswin Mathew, MD | |
|
118 Welsh Rd Unit B, Horsham, PA 19044-2242 | |
| (215) 517-1038 | |
| Not Available |
| Full Name | Dr Aswin Mathew |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 10 Years |
| Location | 118 Welsh Rd Unit B, Horsham, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447547104 | NPI | - | NPPES |
| MT-200501 | Other | PA | PA STATE TRAINING LICENSE |
| 1030173720016 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Abington Memorial Hospital | Abington, PA | Hospital |
| Conemaugh Memorial Medical Center | Johnstown, PA | Hospital |
| Abington Health Lansdale Hospital | Lansdale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dlp Conemaugh Physician Practices Llc | 7315166949 | 253 |
| Abington Medical Specialists Association | 7719872696 | 25 |
| Sanford Bismarck | 9739098575 | 448 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790738011 PECOS PAC ID: 3274437736 Enrollment ID: O20031208000487 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Abington Medical Specialists Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225084528 PECOS PAC ID: 7719872696 Enrollment ID: O20040219000129 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Hr Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881696698 PECOS PAC ID: 0042109902 Enrollment ID: O20040311000028 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Grand View Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568459287 PECOS PAC ID: 8022001924 Enrollment ID: O20040408000680 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Grand View Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669802542 PECOS PAC ID: 8022001924 Enrollment ID: O20140225000367 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Drexel University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902900095 PECOS PAC ID: 5496664740 Enrollment ID: O20140729001682 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Dlp Conemaugh Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932515905 PECOS PAC ID: 7315166949 Enrollment ID: O20140915002522 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Temple Faculty Practice Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881176949 PECOS PAC ID: 0345588711 Enrollment ID: O20190208002623 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Entity Name | Grand View Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1063196509 PECOS PAC ID: 8022001924 Enrollment ID: O20231030002869 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aswin Mathew, MD 118 Welsh Rd Unit B, Horsham, PA 19044-2242 Ph: (215) 517-1038 | Dr Aswin Mathew, MD 118 Welsh Rd Unit B, Horsham, PA 19044-2242 Ph: (215) 517-1038 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In this Foreign Affairs essay, Thomas Bollyky, a senior fellow for global health, economics and development at the Council on Foreign Relations, examines the increase of non-communicable diseases (NCDs) in the developing world.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
› Verified 8 days ago
Dr. Cecelia Florence Roman, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 433 Caredean Dr, Horsham, PA 19044 Phone: 215-823-6050 Fax: 215-823-4425 | |
Jennifer Kostacos, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3 Village Rd Ste 101, Horsham, PA 19044 Phone: 267-207-3100 Fax: 267-207-3111 | |
Peter M Ucciferro, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 118 Welsh Rd Unit A, Horsham, PA 19044 Phone: 215-657-5200 Fax: 215-657-8083 | |
Dr. Matthew Manning Collins, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 118 Welsh Rd Unit B, Horsham, PA 19044 Phone: 215-517-1038 | |
Kira Shteinberg, Internal Medicine Medicare: Medicare Enrolled Practice Location: 680 Blair Mill Rd, Horsham, PA 19044 Phone: 267-965-7962 | |
Kimberly K Lessard, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 118 Welsh Rd Unit A, Horsham, PA 19044 Phone: 215-657-5200 Fax: 215-657-8083 | |
Ned M Weiss, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Village Rd, Ste 10, Horsham, PA 19044 Phone: 215-657-5500 Fax: 215-657-4782 |